Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer

10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb

“…Thus, the results of this study further confirm the results of our previous 8-year follow-up in coronary artery disease patients treated with intracoronary VEGF-A GT. 17 Nearly half of the entire patient population died during the followup. For this reason the number of patients interviewed for this study was relatively low.…”

“…We have recently shown that local intracoronary VEGF-A GT using plasmid/liposome and adenoviral vectors does not increase the incidence of cancer, diabetes or its complications, major cardiac events or arrhythmias compared with a randomized control group in an 8-year follow-up. 17 In this study we analyzed the long-term safety and effects of local catheter-mediated VEGF-A gene transfer to the lower limb arteries. The study population consists of patients who participated in a placebocontrolled peripheral arterial occlusive disease phase II VEGF-A GT trial during the years 1998-2001.…”

VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond

“…Follow-up studies performed at 8 and 10 years after gene therapy in the peripheral and coronary ischemia studies, respectively, however indicated that there were no significant differences in mortality or incidence of major adverse events between the treatment groups. 53,54 A first-generation adenoviral vector is also at the basis of a recently initiated, gene therapy angiogenesis trial aimed at delivering VEGF-D to the ischemic myocardium. In particular, this Phase I, singleblinded, placebo-controlled study entails NOGA-mediated transendocardial injection of escalating doses of vector to patients with coronary heart disease with no other therapeutic options (trial KAT301; http://clinicaltrials.gov/show/NCT01002430).…”

Expression of Proinflammatory Factors, Proangiogenic Factors and Endostatin in Patients with Heart Failure and Different Grades of Collateral Circulation Development

“…One of the latest studies evaluated the efficacy and clinical significance of administration of the VEGF encoding gene [27]. The authors reported a significant improvement in myocardial perfusion in patients who received VEGF in combination with adenoviral vector after 6 months.…”